Tildrakizumab Shows Sustained Real-World Benefit in Japanese Psoriasis Patients Over 52 Weeks
A 52-week Japanese observational study found that tildrakizumab sustained meaningful disease control in real-world psoriasis patients, with 60 percent achieving ...
